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Who we are?
What is Artelis doing (1)
• Young company, created mid 2005
• Based in Brussels, inside the R&D site of the 
Solvay chemical company
• 25 people, 30 by end ‘08, 40 by end ’09
• Pilot unit:
– 500m², with 4 CR BSL2 and BSL3 for cell and 
virus culture
– 3 additional CR under construction
Who we are?
What is Artelis doing (2)
• Design, development and industrialization of:
– Components for “technical disposables”:
• Range of disposable mixing systems for flexible bags –
Jet DriveTM, transferred to ATMI Life Sciences
• Range of stirred tank disposable bioreactors –
NucleoTM, in collaboration with ATMI Life Sciences and 
Pierre Guérin Biolaffite
• We are not in front of the customers, we are not 
suppliers
Who we are?
What is Artelis doing (3)
• Design, development and industrialization of:
– Cell culture-based processes, for the production 
of viruses, viral vectors, antibodies, rec-proteins:
• Focused on disposables
• Focused on high cell density (HCD) processes, by cells 
immobilization
• We target:





• Share some thoughts and data on process 
intensification as a mean to face current 
challenges:
– Need for large quantities of vaccines:
• Influenza: move from eggs to cell culture
• Polio: move from attenuated to inactivated vaccine
• Large cell culture scales will be needed
– Need for cost control & cost reduction
Outline
• Teaching - Ratan Tata (CEO, Tata Motors)
• Process intensification:
– Costs: is the “plastic factory” a valid way for cost 
reduction?
– Capacities: increasing volumetric yields
• Is it a valid way for increasing capacities?
• Is it a valid way for additional cost reduction?
• Teaching - Oscar Wilde (Poet, 19th century)
• Some examples – HCD achievements and targets
Teaching from R. Tata (1)
• Tata Nano launched Feb 2008 at New Delhi 
car show, at 2500$
• Cheapest car in the
world, the new “volks
wagen”
Teaching from R. Tata (2)
• Tata Motors succeeded in developing a 
product:
– Need for large quantities
– Need for cost reduction and cost control
– Without decreasing safety / quality
Teaching from R. Tata (3)
(Business week Feb27 2008)
• How did they do (1) ?
– … looking at everything from scratch:
• “Ghandian engineering” principles: deep frugality with a 
willingness to challenge conventional wisdom
– 40 patents associated with the design of Nano:
• vs 280 patents awarded to GM each year…
• Measuring progress solely by patents creation misses a 
key dimension of innovation: most valuable innovations 
take existing patented components and remix them in a 
way that more effectively serve a large number of 
customers 
Teaching from R. Tata (4)
(Business week Feb27 2008)
• How did they do (2) ?
– Most innovative aspect… modular design:
• Nano is constructed of components that can be built 
and shipped separately to be assembled in a variety of 
locations
• Nano can be sold in kits that are distributed, assembled 
and serviced by local entrepreneurs
• R.Tata to The Times: 
– …we will create entrepreneurs across the country who will 
produce the car
– … we will produce mass items and ship to them as kits; that’s 
my idea of dispersing wealth
Teaching from R. Tata (5)
• Integrate the whole product chain, from early 
research to packaging and distribution: where is 
the cost?
– Challenge current paradigms
– Define targets and the “good enough” product
– Avoid “innovation for innovation”, as a marcom tool
– Main costs they identified are avoided:
• Stocks of finished cars
• Transport of finished cars
Process Intensification
• Costs: is the “plastic factory” a valid way for cost 
reduction?
• Capacities: increasing volumetric yields
– Is it a valid way for increasing capacities?
– Is it a valid way for timelines reduction?
Process Intensification
• Interim conclusions:
– Yes, a plastic factory makes sense for
• Capital investment reduction
• Operational costs reduction
• Financial risk reduction
• Significant reduction of timelines – first on the market
– Yes, increasing volumetric yields makes sense for
• Maximizing chances of supply large amount of doses
• Avoiding risky investment before having clinical results










































































































































• Avoid implementation of L-S separation for perfusion
• Avoid scaling up to large scales (100L would be 
equivalent to 2500L)
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Teaching - Oscar Wilde
• Facts / rationale / perception
“Truth is rarely pure and never simple”,
















• Scales (prototypes) available today:





• Feasibility – biological models
– MDBK cells / Bovine Herpes Virus
– Mab expression in CHO clone from Selexis
– Summary
• Additional experience and validation with:






• MDBK – BHV model (1):
– Screening of cell culture conditions at very small 
scale (5mL of fixed bed):
• Screening parameters:
– Cell density at seeding
– TOI, MOI, media renewal, harvest time
• Up to 15 cultures in parallel
• Predictive of pilot scale experiments
• Cell densities up to 40 – 60 M cells/mL
• Viral production per cell similar to stationary cultures
Process Intensification 
Volumetric Yields
• MDBK – BHV model (2):
– Implementation of better culture conditions at 
pilot scale of 500mL:
• 60 106 cells/mL
• Similar cell densities vs to small scale
• Similar viral specific productivity
Process Intensification 
Volumetric Yields
• MDBK – BHV model (3):
– Culture at pilot scale of 500mL:
Process Intensification 
Volumetric Yields
• MDBK – BHV model (4):
– Comparison with 10L culture with Cytodex1 (6g/L)
– Viral titer:
• 1x108 pfu/mL in classical culture
• 2x109 pfu/mLfixed bed in fixed bed
– Volume reduction: 20
Process Intensification 
Volumetric Yields
• Mab in CHO model (1):
– Same methodology:
• Screening of cell culture conditions at 5mL of fixed bed
• Implement best conditions at 500mL of fixed bed
• Compare to fed-batch process in 100L bioreactor
– Both are 10 days processes
– No savings of cell culture medium
Process Intensification 
Volumetric Yields
• Mab in CHO model (2):
– Results:
• 250 106 cells/mLfixed bed in fixed bed
• 5 106 cells/mL in fed-batch agitated culture
• 20g/L in fixed bed (2g/L/day)
• 250mg/L in fed-batch






























– Scale-up fixed bed bioreactor to 100L
– Implement customized process control unit
– Reach a consistent 25x volume reduction for viral 
processes, compared to reference production on 
Cytodex (human and some vet vaccines)
– Reach a consistent ratio: 1L fixed bed / 300 Rollers 
(vet vaccines, some human products on CHO and 
gene therapy)
– Implement technology for cell therapy




















Process intensification Plastic 
factory
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